These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 20106640)
1. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Catalán V; Gómez-Ambrosi J; Rodríguez A; Ramírez B; Silva C; Rotellar F; Cienfuegos JA; Salvador J; Frühbeck G Nutr Metab Cardiovasc Dis; 2011 Apr; 21(4):245-53. PubMed ID: 20106640 [TBL] [Abstract][Full Text] [Related]
2. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645 [TBL] [Abstract][Full Text] [Related]
3. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. Moschen AR; Molnar C; Wolf AM; Weiss H; Graziadei I; Kaser S; Ebenbichler CF; Stadlmann S; Moser PL; Tilg H J Hepatol; 2009 Oct; 51(4):765-77. PubMed ID: 19664840 [TBL] [Abstract][Full Text] [Related]
4. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Chang YC; Chang TJ; Lee WJ; Chuang LM Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775 [TBL] [Abstract][Full Text] [Related]
5. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460 [TBL] [Abstract][Full Text] [Related]
6. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Auguet T; Terra X; Porras JA; Orellana-Gavaldà JM; Martinez S; Aguilar C; Lucas A; Pellitero S; Hernández M; Del Castillo D; Richart C Clin Biochem; 2013 Feb; 46(3):202-8. PubMed ID: 23174488 [TBL] [Abstract][Full Text] [Related]
7. Visfatin, low-grade inflammation and body mass index (BMI). Samara A; Pfister M; Marie B; Visvikis-Siest S Clin Endocrinol (Oxf); 2008 Oct; 69(4):568-74. PubMed ID: 18248642 [TBL] [Abstract][Full Text] [Related]
8. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models. Mercader J; Granados N; Caimari A; Oliver P; Bonet ML; Palou A Horm Metab Res; 2008 Jul; 40(7):467-72. PubMed ID: 18401839 [TBL] [Abstract][Full Text] [Related]
9. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. Olarescu NC; Ueland T; Lekva T; Dahl TB; Halvorsen B; Aukrust P; Bollerslev J J Clin Endocrinol Metab; 2012 Apr; 97(4):1355-62. PubMed ID: 22319029 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Sun Q; Li L; Li R; Yang M; Liu H; Nowicki MJ; Zong H; Xu J; Yang G Ann Med; 2009; 41(4):311-20. PubMed ID: 19263259 [TBL] [Abstract][Full Text] [Related]
11. The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling. Owczarek AJ; Olszanecka-Glinianowicz M; Kocełak P; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Puzianowska-Kuźnicka M; Grodzicki T; Więcek A; Chudek J Scand J Clin Lab Invest; 2016 Dec; 76(8):632-640. PubMed ID: 27712122 [TBL] [Abstract][Full Text] [Related]
12. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Sommer G; Garten A; Petzold S; Beck-Sickinger AG; Blüher M; Stumvoll M; Fasshauer M Clin Sci (Lond); 2008 Jul; 115(1):13-23. PubMed ID: 19016657 [TBL] [Abstract][Full Text] [Related]
13. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357 [TBL] [Abstract][Full Text] [Related]
14. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Moschen AR; Geiger S; Gerner R; Tilg H Mutat Res; 2010 Aug; 690(1-2):95-101. PubMed ID: 19583971 [TBL] [Abstract][Full Text] [Related]
15. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Ma Y; Cheng Y; Wang J; Cheng H; Zhou S; Li X Diabetes Res Clin Pract; 2010 Oct; 90(1):60-5. PubMed ID: 20621376 [TBL] [Abstract][Full Text] [Related]
16. Visfatin expression is elevated in normal human pregnancy. Morgan SA; Bringolf JB; Seidel ER Peptides; 2008 Aug; 29(8):1382-9. PubMed ID: 18524416 [TBL] [Abstract][Full Text] [Related]
17. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Wang P; van Greevenbroek MM; Bouwman FG; Brouwers MC; van der Kallen CJ; Smit E; Keijer J; Mariman EC Pflugers Arch; 2007 Sep; 454(6):971-6. PubMed ID: 17429683 [TBL] [Abstract][Full Text] [Related]
18. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats. Wang P; Bai C; Xu QY; Xu TY; Su DF; Sassard J; Miao CY Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):894-9. PubMed ID: 20456420 [TBL] [Abstract][Full Text] [Related]
19. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism. Benedict C; Shostak A; Lange T; Brooks SJ; Schiöth HB; Schultes B; Born J; Oster H; Hallschmid M J Clin Endocrinol Metab; 2012 Feb; 97(2):E218-22. PubMed ID: 22090280 [TBL] [Abstract][Full Text] [Related]
20. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Dalamaga M Med Hypotheses; 2012 Nov; 79(5):617-21. PubMed ID: 22922056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]